Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza and Pneumococcal Vaccination in COPD Patients
NCT07640841Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jun 2026
- Primary completion
- Jun 2027
01
Overview
Phase 4, randomised, open-label trial of trivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in influenza and pneumonia (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Number of COPD acute exacerbation events at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trivalent influenza vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
influenzapneumonia
Beyond the preview
Go deeper on NCT07640841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640841.